Aloperine - CAS 56293-29-9
Not Intended for Therapeutic Use. For research use only.
Category:
Inhibitor
Product Name:
Aloperine
Catalog Number:
56293-29-9
CAS Number:
56293-29-9
Description:
Aloperine is an isolated alkaloid in sophora plants such as Sophora alopecuroides L, and exhibits anti-inflammatory, antibacterial, antiviral, and anti-tumor properties.
Molecular Weight:
232.36
Molecular Formula:
C15H24N2
COA:
Inquire
MSDS:
Inquire
Chemical Structure
CAS 56293-29-9 Aloperine

Reference Reading


1.Aloperine executes antitumor effects against multiple myeloma through dual apoptotic mechanisms.
Wang H1,2, Yang S3, Zhou H4, Sun M5, Du L6, Wei M7, Luo M8, Huang J9, Deng H10, Feng Y11, Huang J12, Zhou Y13. J Hematol Oncol. 2015 Mar 15;8:26. doi: 10.1186/s13045-015-0120-x.
BACKGROUND: Aloperine, a natural alkaloid constituent isolated from the herb Sophora alopecuroides displays anti-inflammatory properties in vitro and in vivo. Our group previously demonstrated that aloperine significantly induced apoptosis in colon cancer SW480 and HCT116 cells. However, its specific target(s) remain to be discovered in multiple myeloma (MM) and have not been investigated.
2.Protective effects of aloperine on neonatal rat primary cultured hippocampal neurons injured by oxygen-glucose deprivation and reperfusion.
Ma NT1, Zhou R, Chang RY, Hao YJ, Ma L, Jin SJ, Du J, Zheng J, Zhao CJ, Niu Y, Sun T, Li W, Koike K, Yu JQ, Li YX. J Nat Med. 2015 Oct;69(4):575-83. doi: 10.1007/s11418-015-0928-2. Epub 2015 Jul 5.
Aloperine (ALO), one of the alkaloids isolated from Sophora alopecuroides L., is traditionally used for various diseases including neuronal disorders. This study investigated the protective effects of ALO on neonatal rat primary-cultured hippocampal neurons injured by oxygen-glucose deprivation and reperfusion (OGD/RP). Treatment with ALO (25, 50, and 100 mg/l) attenuated neuronal damage (p < 0.01), with evidence of increased cell viability (p < 0.01) and decreased cell morphologic impairment. Furthermore, ALO increased mitochondrial membrane potential (p < 0.01), but inhibited intracellular-free calcium [Ca(2+)] i (p  < 0.01) elevation in a dose-dependent manner at OGD/RP. ALO also reduced the intracellular reactive oxygen species and malondialdehyde production and enhanced the antioxidant enzymatic activities of catalase, superoxide dismutase, glutathione peroxidase and the total antioxidant capacity. The results suggested that ALO has significant neuroprotective effects that can be attributed to anti-oxidative stress.
3.Topical application of aloperine improves 2,4-dinitrofluorobenzene-induced atopic dermatitis-like skin lesions in NC/Nga mice.
Yuan XY1, Ma HM, Li RZ, Wang RY, Liu W, Guo JY. Eur J Pharmacol. 2011 May 11;658(2-3):263-9. doi: 10.1016/j.ejphar.2011.02.013. Epub 2011 Mar 1.
Aloperine has been shown to inhibit 2,4-dinitrofluorobenzene (DNFB) induced allergic contact dermatitis in BALB/c mice. In the present study, we further investigated the effect of aloperine on DNFB-induced atopic dermatitis-like skin lesions in NC/Nga mice. NC/Nga mice elicited atopic dermatitis-like skin lesions after the topical application of DNFB. Aloperine treatment significantly inhibited dermatitis index and ear thickness in DNFB-treated NC/Nga mice in a dose-dependent manner. Eosinophils, mast cells infiltration into the ears and plasma level of immunoglobulin (Ig) E were also suppressed by aloperine treatment. Finally, cytokine (interleukin (IL)-1β, IL-4, IL-6, IL-10, IL-13, tumor necrosis factor (TNF)-α and interferon (IFN)-γ) productions in ear biopsies homogenates were significantly elevated after DNFB challenge. Topical application of aloperine increased the immunosuppressive cytokine IL-10 level, while it reduced other cytokines production in a dose-dependent manner.
4.Aloperine attenuated neuropathic pain induced by chronic constriction injury via anti-oxidation activity and suppression of the nuclear factor kappa B pathway.
Xu YQ1, Jin SJ2, Liu N1, Li YX3, Zheng J1, Ma L4, Du J1, Zhou R1, Zhao CJ5, Niu Y6, Sun T4, Yu JQ7. Biochem Biophys Res Commun. 2014 Sep 5;451(4):568-73. doi: 10.1016/j.bbrc.2014.08.025. Epub 2014 Aug 12.
OBJECTIVE: To investigate whether aloperine (ALO) has antinociceptive effects on neuropathic pain induced by chronic constriction injury, whether ALO reduces ROS against neuropathic pain, and what are the mechanisms involved in ALO attenuated neuropathic pain.